ABIOLA IZEKOR: Open Payments
NPI 1194455741 · SAN FRANCISCO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$582 in 42 payments from 9 companies in 2025. Trend: 2023 $60 · 2024 $111 · 2025 $582
Food & beverage: $575Education: $8
| Company | Payments | Amount |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 20 | $134 |
| Otsuka America Pharmaceutical, Inc. | 5 | $105 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $101 |
| ABBVIE INC. | 5 | $91 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $69 |
| Janssen Pharmaceuticals, Inc | 1 | $23 |
| Vertical Pharmaceuticals, LLC | 1 | $23 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| Collegium Pharmaceutical, Inc. | 1 | $17 |
Products named: Qelbree, REXULTI, CAPLYTA, VRAYLAR, TRINTELLIX, SPRAVATO, Relexxii, AUSTEDO XR.
Industry payments across CA — which companies pay providers there.
